Abstract A086: NST-628 is a novel molecular glue that inhibits signaling and pathway reactivation in oncogenic RAS-MAPK cancers
Bradley Quade(Sage Therapeutics (United States)), Michael Hale(Takeda (United States)), Ayşegül Özen(Sage Therapeutics (United States)), Arvin C. Dar(Memorial Sloan Kettering Cancer Center), Margit Hagel(Unknown), Xin Huang, Zhong Fang(University of Waterloo), Meagan B. Ryan(Sage Therapeutics (United States)), Brooke M. Swalm(Sage Therapeutics (United States)), Yongxin Han(Merck & Co., Inc., Rahway, NJ, USA (United States)), Steven I. Cohen, Klaus P. Hoeflich(Pivot)
Cited by 1
Related Papers
The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling
|Annual Review of Biochemistry|2011|391